- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01183910
A Novel Oral Natural Extract for the Treatment of Senile Purpura
June 6, 2011 updated by: Nexgen Dermatologics, Inc.
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Safety and Efficacy of a Novel Oral Natural Extract for the Treatment of Senile Purpura
A randomized, double-blind, placebo controlled study to assess the safety and effectiveness of a novel oral natural extract to improve the appearance of the skin of patients with senile purpura.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
75
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Boynton Beach, Florida, United States, 33437
- Berlin Center of Medical Aesthetics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with evidence of purpura on physical exam
Exclusion Criteria:
- Preexisting condition that would not allow the patients to take oral calcium supplement
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Calcium carbonate placebo pill
Placebo medication to treat the appearance of the skin in patients with senile purpura
|
Oral Tablet Taken Twice a Day
|
Active Comparator: Nutraceutical
Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
|
Pill Taken Twice a Day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
IMPROVEMENT IN PATIENT'S SKIN APPEARANCE WITH SENILE PURPURA
Time Frame: 6 WEEKS
|
6 WEEKS
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ADVERSE EFFECTS IN PATIENTS WITH SENILE PURPURA TAKING THIS MEDICATION
Time Frame: 6 WEEKS
|
6 WEEKS
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: JOSHUA M BERLIN, MD, Study Protocol, Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Anticipated)
July 1, 2011
Study Completion (Anticipated)
August 1, 2011
Study Registration Dates
First Submitted
August 16, 2010
First Submitted That Met QC Criteria
August 17, 2010
First Posted (Estimate)
August 18, 2010
Study Record Updates
Last Update Posted (Estimate)
June 8, 2011
Last Update Submitted That Met QC Criteria
June 6, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 021775
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PURPURA
-
Turkish Hematology AssociationSanofiRecruitingTTP - Thrombotic Thrombocytopenic PurpuraTurkey
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
Peking Union Medical College HospitalNot yet recruitingThrombotic Thrombocytopenic Purpura, AcquiredChina
-
Fundación Española de Hematología y HemoterapíaRecruitingAcquired Thrombotic Thrombocytopenic PurpuraSpain, Portugal
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
TakedaAvailableThrombotic Thrombocytopenic Purpura (TTP)
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
-
SanofiCompletedThrombotic Thrombocytopenic PurpuraJapan
-
SanofiCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
-
TakedaShire; Takeda Development Center Americas, Inc.RecruitingThrombotic Thrombocytopenic Purpura (TTP)China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Clinical Trials on Calcium Carbonate
-
Unity Health TorontoCanadian Institutes of Health Research (CIHR)CompletedEnd-stage Renal DiseaseCanada
-
BayerRecruitingHealthy Volunteers | Heartburn | Indigestion | Stomach Acid Related Symptoms | Nocturnal Stomach Acid Related SymptomsUnited Kingdom
-
Karolinska University HospitalCompleted
-
China Medical University HospitalRecruitingRheumatoid Arthritis | Osteopenia or OsteoporosisTaiwan
-
Harvard School of Public Health (HSPH)Ifakara Health Institute; St. John's Research Institute; Africa Academy for Public...CompletedPregnancy RelatedTanzania, India
-
BayerCompleted
-
University of Colorado, DenverRecruitingAging | Vascular Stiffness | Vascular DilationUnited States
-
Gary StrikerCompleted
-
University College, LondonActive, not recruitingChronic Kidney DiseasesUnited Kingdom
-
Integrative Health Technologies, Inc.UnknownOsteopenia, OsteoporosisUnited States